Showing results (21-30 of 683) with videos related to
Sort By:
Pageof 69
Clinical and Translational Gastroenterology|May 16, 2022
Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte SubsetsEmily Becker, Anna Schweda, Karen A-M Ullrich, et al.Inflammatory Bowel Diseases|July 15, 2017
Characterization and Expansion of Autologous GMP-ready Regulatory T Cells for TREG-based Cell Therapy in Patients with Ulcerative ColitisCaroline J Voskens, Anika Fischer, Susanne Roessner, et al.Therapeutic Advances in Gastroenterology|July 5, 2022
Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitisLaura Besendorf, Tanja M Müller, Carol-Immanuel Geppert, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 18, 2014
A key regulatory role for Vav1 in controlling lipopolysaccharide endotoxemia via macrophage-derived IL-6Stefanie Zenker, Julia Panteleev-Ivlev, Stefan Wirtz, et al.Inflammatory Bowel Diseases|May 23, 2018
Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-sMarie-Theres Binder, Emily Becker, Maximilian Wiendl, et al.Gut|June 15, 2007
The T-box transcription factor eomesodermin controls CD8 T cell activity and lymph node metastasis in human colorectal cancerImke Atreya, Carl C Schimanski, Christoph Becker, et al.Seminars in Immunology|December 17, 2025
New insights into Th9 cells in inflammatory bowel diseasesMarkus F NeurathScience Translational Medicine|December 14, 2022
Targeting cytokines in inflammatory bowel diseaseMarkus F NeurathNature Reviews. Immunology|March 15, 2024
Strategies for targeting cytokines in inflammatory bowel diseaseMarkus F NeurathCytokine & Growth Factor Reviews|December 20, 2018
IL-23 in inflammatory bowel diseases and colon cancerMarkus F NeurathPageof 69